AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24848782 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of analgesia (LIA) in addition to femoral nerve block (FNB)
Number of subjects: 46
Study 21688876 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily estimated blood alcohol concentration (eBAC)
Number of subjects: 1350
Study 21688876 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective intoxication
Number of subjects: 1350
Study 21688876 — intervention group
Group type: EXPERIMENTAL
Intervention: Driving after drinking
Number of subjects: 1350
Study 21688876 — intervention group
Group type: EXPERIMENTAL
Intervention: eBAC above legal limit
Number of subjects: 1350
Study 19721382 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal advocacy of influenza vaccination by community pharmacists in the intervention group.
Number of subjects: 1776
Study 19721382 — intervention group
Group type: COMPARATOR
Intervention: Control pharmacy group (no advocacy).
Number of subjects: 1776
Study 17962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (50 mg)
Number of subjects: 49
Study 17962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (90 mg)
Number of subjects: 49
Study 17962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-controlled extended-release methylphenidate (108 mg)
Number of subjects: 49
Study 17962423 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic-controlled extended-release methylphenidate (54 mg)
Number of subjects: 49
Study 17962423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15152054 — intervention group
Group type: EXPERIMENTAL
Intervention: Children measured under light Sevoflurane anesthesia
Number of subjects: 10
Study 15152054 — intervention group
Group type: COMPARATOR
Intervention: Children measured awake
Number of subjects: 10
Study 12228819 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil (1 Malarone tablet per day for 20 weeks; n=148)
Number of subjects: 297
Study 12228819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=149)
Number of subjects: 297
Study 12228819 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 297
Study 9689557 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg isosorbide dinitrate
Number of subjects: 20
Study 9689557 — intervention group
Group type: COMPARATOR
Intervention: Control group (clinically healthy subjects)
Number of subjects: 20
Study 8082525 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg three times a day)
Number of subjects: 96
Study 8082525 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (mean dose 4.3 mg/day)
Number of subjects: 96
Study 8082525 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet three times a day)
Number of subjects: 96
Study 2687557 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin therapy
Number of subjects: 88
Study 2687557 — intervention group
Group type: EXPERIMENTAL
Intervention: Capoten monotherapy
Number of subjects: 88
Study 2687557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with glycosides and saluretics
Number of subjects: 88
Study 30920983 — intervention group
Group type: EXPERIMENTAL
Intervention: Profound neuromuscular blockade (posttetanic count 1 to 3)
Number of subjects: 96
Study 30920983 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four count 1 to 3)
Number of subjects: 96
Study 28578330 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS over the dACC to mPFC for 5 sessions over 5 days
Number of subjects: 13
Study 28578330 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 5 sessions over 5 days
Number of subjects: 13
Study 26237112 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain
Number of subjects: 394
Study 26237112 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pain
Number of subjects: 394
Study 26237112 — intervention group
Group type: EXPERIMENTAL
Intervention: No pain
Number of subjects: 394
Study 26237112 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthritis pain
Number of subjects: 394
Study 24221841 — intervention group
Group type: EXPERIMENTAL
Intervention: WE CALL (study initiated phone support/information provision)
Number of subjects: 186
Study 24221841 — intervention group
Group type: COMPARATOR
Intervention: YOU CALL (participant can contact a resource person)
Number of subjects: 186
Study 24221841 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186
Study 24221841 — intervention group
Group type: EXPERIMENTAL
Intervention: WE CALL
Number of subjects: 186
Study 21226859 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow moderate-pressure recruitment manoeuvre (SLRM)
Number of subjects: 16
Study 21226859 — intervention group
Group type: COMPARATOR
Intervention: Vital capacity recruitment manoeuvre (VICM)
Number of subjects: 16
Study 19622979 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt needles
Number of subjects: 194
Study 19622979 — intervention group
Group type: COMPARATOR
Intervention: Sharp needles
Number of subjects: 194
Study 16706572 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400mg three times daily)
Number of subjects: 0
Study 16706572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14740578 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom management intervention using the Health Buddy device
Number of subjects: 0
Study 14740578 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11762562 — intervention group
Group type: EXPERIMENTAL
Intervention: 530-calorie breakfast after a 12-hour fast
Number of subjects: 28
Study 11762562 — intervention group
Group type: EXPERIMENTAL
Intervention: 550-calorie meals (high-fat, high-protein, high-carbohydrate) after a 12-hour fast
Number of subjects: 28
Study 9420396 — intervention group
Group type: EXPERIMENTAL
Intervention: Early appendicectomy
Number of subjects: 0
Study 9420396 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 0
Study 8500242 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 0
Study 8500242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8500242 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 8500242 — intervention group
Group type: EXPERIMENTAL
Intervention: EPSS > or = 21 with Rs/THs > or = 2.5
Number of subjects: 0
Study 8500242 — intervention group
Group type: EXPERIMENTAL
Intervention: EPSS < 21
Number of subjects: 0
Study 3430953 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (mean dose = 172 mg)
Number of subjects: 10
Study 3430953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (mean dose = 4.3 mg)
Number of subjects: 10
Study 3430953 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 10
Study 3430953 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide
Number of subjects: 10
Study 30442187 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter
Number of subjects: 275
Study 30442187 — intervention group
Group type: COMPARATOR
Intervention: No Letter
Number of subjects: 275
Study 26891756 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily added to aspirin 81 mg/day
Number of subjects: 70
Study 26891756 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to aspirin 81 mg/day
Number of subjects: 70
Study 24837543 — intervention group
Group type: EXPERIMENTAL
Intervention: Validated telephone-based diet counseling intervention
Number of subjects: 464
Study 24837543 — intervention group
Group type: COMPARATOR
Intervention: Published diet guideline (Control)
Number of subjects: 464
Study 24837543 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 464
Study 22434340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g diluted in 10 ml of lidocaine 1% administered periprostatically and ciprofloxacin orally
Number of subjects: 150
Study 22434340 — intervention group
Group type: COMPARATOR
Intervention: 10 ml lidocaine 1% administered before TRUS gpb
Number of subjects: 150
Study 20615145 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 60
Study 20615145 — intervention group
Group type: COMPARATOR
Intervention: No stent placement
Number of subjects: 60
Study 18665388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (including coenzyme Q(10))
Number of subjects: 19
Study 18665388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16254100 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564
Study 16254100 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 564
Study 12540320 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate catheterization and surgical intervention
Number of subjects: 0
Study 12540320 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 0
Study 10190614 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed reduction and plaster application
Number of subjects: 98
Study 10190614 — intervention group
Group type: COMPARATOR
Intervention: Kapandji-pinning
Number of subjects: 98
Study 7799039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose chemotherapy (CMF: cyclophosphamide 50 mg/m2 orally on days 1 to 14, methotrexate 15 mg/m2 intravenously on days 1 and 8, fluorouracil 350 mg/m2 intravenously on days 1 and 8) for 2 years
Number of subjects: 452
Study 7799039 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 452
Study 7799039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged low-dose chemotherapy
Number of subjects: 452
Study 2405920 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum beta 2 microglobulin levels < 6 micrograms/mL
Number of subjects: 612
Study 2405920 — intervention group
Group type: COMPARATOR
Intervention: Serum beta 2 microglobulin levels ≥ 6 micrograms/mL
Number of subjects: 612
Study 6986896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal flunisolide (300 microgram/day)
Number of subjects: 60
Study 6986896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6986896 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunisolide
Number of subjects: 60
Study 6986896 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate
Number of subjects: 60
Study 31343945 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity resistance exercise (5 sets of 10 repetitions at 75% of 1 repetition maximum)
Number of subjects: 52
Study 31343945 — intervention group
Group type: COMPARATOR
Intervention: Sham control (seated rest)
Number of subjects: 52
Study 28732397 — intervention group
Group type: EXPERIMENTAL
Intervention: CSO events
Number of subjects: 0
Study 25441259 — intervention group
Group type: EXPERIMENTAL
Intervention: GOALS assessment
Number of subjects: 10
Study 24468920 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioural therapy with sudden gains
Number of subjects: 81
Study 24468920 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy without sudden gains
Number of subjects: 81
Study 24468920 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioural therapy with gradual gains
Number of subjects: 81
Study 22694829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg q3w x 4 doses) + gp100 (1 mg q3w x 4 doses)
Number of subjects: 676
Study 22694829 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab (3 mg/kg q3w x 4 doses) + placebo
Number of subjects: 676
Study 22694829 — intervention group
Group type: COMPARATOR
Intervention: gp100 vaccine + placebo
Number of subjects: 676
Study 19946231 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter closure using Amplatzer Septal Occluder (ASO)
Number of subjects: 100
Study 19946231 — intervention group
Group type: COMPARATOR
Intervention: Open-heart surgery
Number of subjects: 100
Study 17300626 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Number of subjects: 43
Study 17300626 — intervention group
Group type: COMPARATOR
Intervention: Conventional twice-daily regimen of artemether-lumefantrine (AL) with 200 ml flavoured milk for 3 days
Number of subjects: 43
Study 17300626 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-dose arm (twice-daily regimen)
Number of subjects: 43
Study 17300626 — intervention group
Group type: COMPARATOR
Intervention: Three-dose arm (once-daily regimen)
Number of subjects: 43
Study 15673856 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 60
Study 15673856 — intervention group
Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 60
Study 12845653 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihistamine users
Number of subjects: 3133
Study 9869600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedotozine (100 mg intravenous infusion)
Number of subjects: 14
Study 9869600 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 14
Study 8888088 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin
Number of subjects: 20
Study 8888088 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 20
Study 8888088 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam plus vancomycin and Imipenem-cilastatin
Number of subjects: 20
Study 2072147 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized dosing of etoposide (target WBC nadir of 1,700/microL)
Number of subjects: 45
Study 2072147 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose of etoposide (125 mg/m2/d)
Number of subjects: 45
Study 7162387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pangamic acid (6 tablets of 50 mg per day)
Number of subjects: 16
Study 31694108 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized preoperative dietary management
Number of subjects: 40
Study 31694108 — intervention group
Group type: COMPARATOR
Intervention: Traditional fasting program
Number of subjects: 40
Study 28931149 — intervention group
Group type: EXPERIMENTAL
Intervention: B-GOS (2.7g daily for 7-15 days)
Number of subjects: 523
Study 28931149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 523
Study 26195619 — intervention group
Group type: COMPARATOR
Intervention: Classic thermoplastic wrist splint
Number of subjects: 24
Study 26195619 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist splint with metacarpophalangeal unit
Number of subjects: 24
Study 25103779 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 2 sessions
Number of subjects: 390
Study 25103779 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality-targeted interventions (PI) - 2 sessions
Number of subjects: 390
Study 25103779 — intervention group
Group type: COMPARATOR
Intervention: Assessment Feedback/Information (AF/I) - 1 session
Number of subjects: 390
Study 22468907 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist adherence to concrete cognitive therapy techniques
Number of subjects: 105
Study 22468907 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of the therapeutic alliance
Number of subjects: 105
Study 22468907 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline symptom severity × CT techniques interaction
Number of subjects: 105
Study 19127072 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 45
Study 19127072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 17854740 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day orally for 24 weeks
Number of subjects: 0
Study 17854740 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg/day orally
Number of subjects: 0
Study 16382063 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued transfusion
Number of subjects: 79
Study 16382063 — intervention group
Group type: COMPARATOR
Intervention: Transfusion-halted group
Number of subjects: 79
Study 12564664 — intervention group
Group type: EXPERIMENTAL
Intervention: Otic powder (Auricularum)
Number of subjects: 67
Study 12564664 — intervention group
Group type: COMPARATOR
Intervention: Otic drops (Dex‐Otic)
Number of subjects: 67
Study 9674632 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (angiotensin-converting enzyme inhibitor)
Number of subjects: 27
Study 9674632 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (calcium antagonist)
Number of subjects: 27
Study 7534331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (100 micrograms subcutaneously, twice daily for 4 weeks)
Number of subjects: 11
Study 7534331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (octreotide vehicle for 4 weeks)
Number of subjects: 11
Study 7534331 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 11
Study 2361714 — intervention group
Group type: COMPARATOR
Intervention: WHO standard ORS
Number of subjects: 75
Study 2361714 — intervention group
Group type: EXPERIMENTAL
Intervention: Super ORS
Number of subjects: 75
Study 2361714 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice water electrolytes solution
Number of subjects: 75
Study 375343 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 50 mg
Number of subjects: 24
Study 375343 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 100 mg
Number of subjects: 24
Study 375343 — intervention group
Group type: EXPERIMENTAL
Intervention: BAY g 5421 (Acarbose) 200 mg
Number of subjects: 24
Study 375343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31468418 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (6 g/day) for 2 weeks prior to and 3 days following resistance exercise
Number of subjects: 29
Study 31468418 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 29
Study 31468418 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation (6 g/day)
Number of subjects: 29
Study 28165562 — intervention group
Group type: EXPERIMENTAL
Intervention: icotinib hydrochloride
Number of subjects: 120
Study 28165562 — intervention group
Group type: COMPARATOR
Intervention: erlotinib
Number of subjects: 120
Study 25963602 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced food away from home
Number of subjects: 170
Study 24238469 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight rehabilitation (target weight between the 15th and 20th BMI percentile)
Number of subjects: 172
Study 21890887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine 10 mg
Number of subjects: 89
Study 21890887 — intervention group
Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 10 mg
Number of subjects: 89
Study 21890887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric bupivacaine 10 mg
Number of subjects: 89
Study 18984669 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic euglycemic clamp with LPS (insulin infusion at 10 or 40 mU.m(‐2).min(‐1))
Number of subjects: 18
Study 18984669 — intervention group
Group type: COMPARATOR
Intervention: Control group (hyperinsulinemic euglycemic clamp without LPS)
Number of subjects: 18
Study 17087800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 0
Study 17087800 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 0
Study 15019315 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency-Doubling Technology (FDT) perimeter
Number of subjects: 40
Study 11520781 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 1 microg/kg
Number of subjects: 120
Study 11520781 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rHuMGDF 3 microg/kg
Number of subjects: 120
Study 11520781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 9716581 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha)
Number of subjects: 322
Study 9716581 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 322
Study 7934716 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to pay (WTP) for a hypothetical intervention offering a 99% chance of healthy lung functioning and a 1% chance of death
Number of subjects: 102
Study 7934716 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard gamble
Number of subjects: 102
Study 7934716 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-retest reliability of WTP
Number of subjects: 102
Study 7934716 — intervention group
Group type: COMPARATOR
Intervention: Health status and preference measurements (excluding WTP)
Number of subjects: 102
Study 2954145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222) at 90 anti‐Xa units/kg bolus + 1,000 anti‐Xa units/hour infusion (regimen 1)
Number of subjects: 8
Study 2954145 — intervention group
Group type: COMPARATOR
Intervention: Standard heparinization regimen (100 IU/kg) (regimen 2)
Number of subjects: 8
Study 2954145 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (CY 222) at 300 anti‐Xa units/kg bolus (regimen 3)
Number of subjects: 8
Study 31399910 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain diet (WG-D)
Number of subjects: 75
Study 31399910 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit and vegetable diet (F&V)
Number of subjects: 75
Study 31399910 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined whole grain and F&V diet (WGFV-D)
Number of subjects: 75
Study 31399910 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 30343856 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 517
Study 30343856 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 517
Study 28393773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 0.5 μg/kg/h
Number of subjects: 0
Study 28393773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26381921 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance Training (ET)
Number of subjects: 40